Production & Manufacturing

UNDBIO, a South Korean pharmaceutical company focused on diabetic care, will spend $100 million to build an insulin manufacturing facility in West Virginia. The project is expected to create 200 new jobs in the first three years, according to an April...

Lonza announces the start of new mid-scale manufacturing assets at its API manufacturing center in Nansha, China. Commercial mid-scale operations are now underway at the expanded manufacturing facility, which was part of a CHF 20 million investment announced in...

For years, global healthcare systems have been facing the triple threat of rising incidences of long-term conditions (LTC), aging populations and dwindling resources. At the same time, we have seen worldwide calls for affordable medicines – from the Jan...

The global oral solid dosage (OSD) contract manufacturing market is anticipated to reach $54.7 billion in value by 2030, exhibiting a compound annual growth rate (CAGR) of 6%, according to a market analysis. As per data, oral solids are the...

The global pharmaceutical contract manufacturing market is anticipated to reach $130.2 billion by 2026 as a result of increasing demand for pharmaceuticals, particularly in developing economies. In 2020, the market was estimated to be worth $100 billion. Market research indicates...

A recent survey found that 86.9% of biopharmaceutical businesses outsource at least a portion of their operations, which has contributed to the $14 billion market for biopharmaceutical contract manufacturing. Over the next ten years, the investigators predict a very bright...

Bribes and rebate arrangements involving drugmakers and pharma middlemen are all being investigated by US regulators, with a particular focus on rising insulin prices. The Federal Trade Commission (FTC) announced recently that it would step up enforcement against practises...